Ancora Advisors LLC Invests $188,000 in Zimmer Biomet Holdings Inc (ZBH) Stock

Ancora Advisors LLC acquired a new stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,427 shares of the medical equipment provider’s stock, valued at approximately $188,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Welch Group LLC bought a new position in Zimmer Biomet in the third quarter worth $78,882,000. Whitener Capital Management Inc. acquired a new position in Zimmer Biomet during the third quarter worth $109,000. Girard Partners LTD. acquired a new position in Zimmer Biomet during the third quarter worth $114,000. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Zimmer Biomet by 5,200.0% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,007 shares of the medical equipment provider’s stock valued at $112,000 after buying an additional 988 shares in the last quarter. Finally, Twin Tree Management LP increased its stake in shares of Zimmer Biomet by 198.0% in the third quarter. Twin Tree Management LP now owns 1,208 shares of the medical equipment provider’s stock valued at $159,000 after buying an additional 2,441 shares in the last quarter. 87.92% of the stock is owned by institutional investors.

ZBH has been the topic of several recent research reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $150.00 price target on shares of Zimmer Biomet in a report on Monday, August 27th. Oppenheimer set a $135.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a report on Thursday. BTIG Research initiated coverage on Zimmer Biomet in a research report on Thursday, August 16th. They issued a “neutral” rating on the stock. Needham & Company LLC lowered Zimmer Biomet from a “strong-buy” rating to a “buy” rating and set a $150.00 target price on the stock. in a research report on Monday, August 13th. Finally, Leerink Swann lowered their price target on Zimmer Biomet from $146.00 to $141.00 and set an “outperform” rating on the stock in a research report on Monday, October 29th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have assigned a buy rating to the company. Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $134.90.

In other news, VP Chad F. Phipps sold 30,100 shares of the business’s stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $132.37, for a total value of $3,984,337.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.71% of the stock is currently owned by corporate insiders.

Shares of ZBH stock opened at $112.91 on Friday. The stock has a market cap of $22.84 billion, a price-to-earnings ratio of 14.06, a PEG ratio of 2.27 and a beta of 1.16. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.89 and a quick ratio of 0.96. Zimmer Biomet Holdings Inc has a 12-month low of $104.28 and a 12-month high of $134.55.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Friday, October 26th. The medical equipment provider reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.03. Zimmer Biomet had a return on equity of 12.88% and a net margin of 22.42%. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the previous year, the business earned $1.72 EPS. Zimmer Biomet’s revenue was up 1.3% compared to the same quarter last year. Equities research analysts anticipate that Zimmer Biomet Holdings Inc will post 7.64 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/12/07/ancora-advisors-llc-invests-188000-in-zimmer-biomet-holdings-inc-zbh-stock.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: Reverse Stock Split

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply